3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2/3
2
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
2
Carcinoma in Situ
2
Virus Diseases
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Adenoviridae Infections
1
Interventions
Gemcitabine
6
Carboplatin
3
valrubicin
2
Cisplatin
2
vinflunine
1
toripalimab
1
pertuzumab
1
disitamab vedotin
1
cabazitaxel
1
apaziquone
1
XRP6258
1
Watchful Waiting
1
Vinblastine
1
Trastuzumab
1
Transurethral Resection of Bladder
1
Tranexamic Acid
1
Saline Solution
1
RC48 antibody
1
Oncolytic Virotherapy
1
Mitomycin
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Lapatinib
1
Interferons
1
Interferon-alpha
1
Gabapentin
1
Circulating Tumor DNA
1
Celecoxib
1
BCG Vaccine
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Urinary Bladder Neoplasms
×
valrubicin
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled
NCT01316874
2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3
Completed
90 enrolled